查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1621585

疫苗佐剂市场：按产品、给药途径、疾病和应用 - 全球预测 2025-2030

Vaccine Adjuvants Market by Product (Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants), Route of Administration (Intradermal, Intramuscular, Intranasal), Disease, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年疫苗佐剂市值为8.2565亿美元，预计2024年将达到8.8418亿美元，复合年增长率为7.88%，到2030年将达到14.042亿美元。

疫苗佐剂是透过调节免疫反应来提高疫苗有效性的重要成分。对佐剂的需求在于其能够增强对抗原的免疫反应，减少所需抗原的量，并提高疫苗的稳定性，特别是在开发针对爱滋病毒、疟疾和癌症等挑战性疾病的新疫苗方面已成为当务之急。特别是，它对于开发针对爱滋病毒、疟疾和癌症等不治之症的新疫苗至关重要。这些疫苗主要用作感染疾病的预防性疫苗以及慢性病和癌症的治疗性疫苗。典型的最终用途领域包括製药公司、学术研究机构和生技公司。市场发展受到感染疾病和慢性病日益普及、对免疫计划的日益关注、佐剂配方的进步以及政府对疫苗开发的支持政策的影响。最近的技术创新，例如新的输送系统和下一代佐剂配方，提供了成长机会。为了利用这些优势，相关人员应专注于扩大策略伙伴关係和研发投资，特别是在免疫需求未被满足的新兴市场。然而，他们面临挑战，例如疫苗核准的严格监管指南、免疫抗原性问题以及与佐剂相关的潜在副作用，这些可能会阻碍采用率。高研发和生产成本也是许多公司的限制因素。创新领域包括开发可诱导更广泛免疫反应的佐剂、儿科佐剂和抗流行病佐剂，这可以提供显着的市场优势。该市场竞争激烈，强调以研究主导的成长策略。总体而言，确保安全性和有效性的辅助技术进步以及促进核准顺利的监管策略对于获得市场占有率至关重要。透过与政府和非政府组织合作，继续走在创新前沿的公司将最有能力在不断发展的疫苗开发领域取得成功。

主要市场统计
基准年[2023] 8.2565亿美元
预计年份 [2024] 88418万美元
预测年份 [2030] 1,404.2 百万美元
复合年增长率（%） 7.88%

市场动态：揭示快速发展的疫苗佐剂市场的关键市场洞察

供需的动态交互作用正在改变疫苗佐剂市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 感染疾病和通用感染疾病的增加
    • 需要提高疫苗的有效性
    • 畜牧业的发展和相关疾病的流行
  • 市场限制因素
    • 矿物佐剂与重组蛋白及次单位疫苗的不相容性
  • 市场机会
    • 增加组合佐剂的潜力
    • 加大疫苗研发力度
  • 市场挑战
    • 资本密集且耗时的开发与核准流程

波特的五力战略工具驾驭疫苗佐剂市场

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对疫苗佐剂市场的影响

外部宏观环境因素对疫苗佐剂市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解疫苗佐剂市场的竞争状况

疫苗佐剂市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV定位矩阵疫苗佐剂市场供应商绩效评估

FPNV定位矩阵是评估疫苗佐剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製疫苗佐剂市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对疫苗佐剂市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病和通用感染疾病的发生率增加
      • 需要提高疫苗的有效性
      • 畜牧业的扩张和相关疾病的传播
    • 抑制因素
      • 矿物佐剂与重组蛋白及次单位疫苗的不相容性
    • 机会
      • 复合佐剂的潜力不断增长
      • 扩大疫苗开发
    • 任务
      • 资本密集且耗时的开发与核准流程
  • 市场区隔分析
    • 疾病：使用疫苗佐剂来提高癌症疫苗的有效性激增
    • 产品：佐剂乳剂在免疫力较弱的人中越来越受欢迎。
    • 应用：增加人类疫苗中疫苗佐剂的使用
    • 给药途径：透过皮内给药增加疫苗佐剂的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章疫苗佐剂市场：副产品

  • 佐剂乳剂
  • 复方佐剂
  • 矿物佐剂
  • 颗粒佐剂

第七章疫苗佐剂市场：依给药途径分类

  • 皮内
  • 肌肉注射
  • 鼻内
  • 口服
  • 皮下的

第八章 疫苗佐剂市场：依疾病分类

  • 癌症
  • 感染疾病

第九章疫苗佐剂市场：依应用分类

  • 人类
  • 兽医

第十章 美洲疫苗佐剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太疫苗佐剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲疫苗佐剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 普立兹克分子工程学院开始产学合作开发下一代疫苗
    • Croda Partners 疫苗佐剂
    • 牛津大学开发的 R21/Matrix M 疟疾疫苗获准在加纳使用
  • 战略分析和建议

公司名单

  • Agenus Inc.
  • Aphios Corporation
  • Bioveta, AS
  • Croda International PLC
  • CSL Limited
  • Dynavax Technologies Corporation
  • GlaxoSmithKline PLC
  • Hayashibara Co., Ltd. by NAGASE & CO., LTD.
  • InvivoGen
  • Merck KGaA
  • Novavax, Inc.
  • OZ Biosciences SAS
  • Pacific GeneTech Limited
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-02026C4C8667

The Vaccine Adjuvants Market was valued at USD 825.65 million in 2023, expected to reach USD 884.18 million in 2024, and is projected to grow at a CAGR of 7.88%, to USD 1,404.20 million by 2030.

Vaccine adjuvants are critical components used to enhance the efficacy of vaccines by modulating the immune response. The necessity of adjuvants lies in their ability to enhance immune reactions to antigens, reduce the amount of antigen required, and improve vaccine stability, making them indispensable in developing new vaccines, especially for challenging diseases like HIV, malaria, and cancer. They are predominantly applied in prophylactic vaccines for infectious diseases and therapeutic vaccines targeting chronic diseases and cancers. Key end-use sectors include pharmaceutical companies, academic research institutions, and biotechnology firms. Market growth is influenced by the rising prevalence of infectious and chronic diseases, increasing focus on immunization programs, advancements in adjuvant formulations, and supportive government policies for vaccine development. Recent technological innovations, such as novel delivery systems and next-generation adjuvant formulations, present opportunities for growth. To capitalize on these, stakeholders should focus on strategic partnerships and increased R&D investments, especially in emerging markets with unmet immunization needs. However, the market faces challenges such as stringent regulatory guidelines for vaccine approval, immunogenicity concerns, and potential side effects associated with adjuvants, which can hinder adoption rates. The high cost of research and production can also pose a limitation for many firms. Areas ripe for innovation include the development of adjuvants that can induce broader immune responses, pediatric-specific adjuvants, and adjuvants for use in pandemic preparedness, which could offer significant market advantages. The market is highly competitive, with a strong emphasis on research-driven growth strategies. Overall, advancing adjuvant technologies that ensure safety and efficacy, along with regulatory strategies that facilitate smoother approvals, will be vital for capturing market share. Firms that stay ahead in innovation, forming alliances with both governmental and non-governmental organizations, will be best positioned for success in the evolving landscape of vaccine development.

KEY MARKET STATISTICS
Base Year [2023] USD 825.65 million
Estimated Year [2024] USD 884.18 million
Forecast Year [2030] USD 1,404.20 million
CAGR (%) 7.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccine Adjuvants Market

The Vaccine Adjuvants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of infectious and zoonotic diseases
    • Need to increase the effectiveness of vaccines
    • Growth in livestock operations and prevalence of associated diseases
  • Market Restraints
    • Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
  • Market Opportunities
    • Rising potential of combination adjuvants
    • Increasing development of vaccines
  • Market Challenges
    • Capital-intensive and time-consuming development and approval process

Porter's Five Forces: A Strategic Tool for Navigating the Vaccine Adjuvants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccine Adjuvants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccine Adjuvants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccine Adjuvants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccine Adjuvants Market

A detailed market share analysis in the Vaccine Adjuvants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccine Adjuvants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccine Adjuvants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccine Adjuvants Market

A strategic analysis of the Vaccine Adjuvants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Adjuvants Market, highlighting leading vendors and their innovative profiles. These include Agenus Inc., Aphios Corporation, Bioveta, A.S., Croda International PLC, CSL Limited, Dynavax Technologies Corporation, GlaxoSmithKline PLC, Hayashibara Co., Ltd. by NAGASE & CO., LTD., InvivoGen, Merck KGaA, Novavax, Inc., OZ Biosciences SAS, Pacific GeneTech Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vaccine Adjuvants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants, and Particulate Adjuvants.
  • Based on Route of Administration, market is studied across Intradermal, Intramuscular, Intranasal, Oral, and Subcutaneous.
  • Based on Disease, market is studied across Cancer and Infectious Diseases.
  • Based on Application, market is studied across Human and Veterinary.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of infectious and zoonotic diseases
      • 5.1.1.2. Need to increase the effectiveness of vaccines
      • 5.1.1.3. Growth in livestock operations and prevalence of associated diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising potential of combination adjuvants
      • 5.1.3.2. Increasing development of vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Capital-intensive and time-consuming development and approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines
    • 5.2.2. Product: Increasing preference for adjuvant emulsions for those with compromised immune systems
    • 5.2.3. Application: Increasing use of vaccine adjuvants for human vaccines
    • 5.2.4. Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccine Adjuvants Market, by Product

  • 6.1. Introduction
  • 6.2. Adjuvant Emulsions
  • 6.3. Combination Adjuvants
  • 6.4. Mineral Adjuvants
  • 6.5. Particulate Adjuvants

7. Vaccine Adjuvants Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intradermal
  • 7.3. Intramuscular
  • 7.4. Intranasal
  • 7.5. Oral
  • 7.6. Subcutaneous

8. Vaccine Adjuvants Market, by Disease

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Infectious Diseases

9. Vaccine Adjuvants Market, by Application

  • 9.1. Introduction
  • 9.2. Human
  • 9.3. Veterinary

10. Americas Vaccine Adjuvants Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaccine Adjuvants Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaccine Adjuvants Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Pritzker School of Molecular Engineering enters Academic-Industry partnership to create Next Generation vaccines
    • 13.3.2. Croda Partners on Vaccine Adjuvants
    • 13.3.3. R21/Matrix-M Malaria Vaccine Developed By University Of Oxford Receives Regulatory Clearance For Use In Ghana
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agenus Inc.
  • 2. Aphios Corporation
  • 3. Bioveta, A.S.
  • 4. Croda International PLC
  • 5. CSL Limited
  • 6. Dynavax Technologies Corporation
  • 7. GlaxoSmithKline PLC
  • 8. Hayashibara Co., Ltd. by NAGASE & CO., LTD.
  • 9. InvivoGen
  • 10. Merck KGaA
  • 11. Novavax, Inc.
  • 12. OZ Biosciences SAS
  • 13. Pacific GeneTech Limited
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. VACCINE ADJUVANTS MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINE ADJUVANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINE ADJUVANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINE ADJUVANTS MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ADJUVANT EMULSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COMBINATION ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MINERAL ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATE ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023